Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/11806
Title: Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15.
Authors: Martinez-Martinez, Laura
Lleixà, Ma Cinta
Boera-Carnicero, Gemma
Cortese, Andrea
Devaux, Jérôme
Siles, Ana
Rajabally, Yusuf
Martinez-Piñeiro, Alicia
Carvajal, Alejandra
Pardo, Julio
Delmont, Emilien
Attarian, Shahram
Diaz-Manera, Jordi
Callegari, Ilaria
Marchioni, Enrico
Franciotta, Diego
Benedetti, Luana
Lauria, Guiseppe
de la Calle Martin, Oscar
Juárez, Cándido
Illa, Isabel
Querol, Luis
Keywords: Antibodies;CIDP;HLA DRB1*15;NF155
metadata.dc.subject.mesh: Adult
Aged
Autoantibodies
Autoantigens
Case-Control Studies
Cell Adhesion Molecules
Female
Gene Frequency
Genetic Predisposition to Disease
Genotype
HLA-DRB1 Chains
Humans
Male
Middle Aged
Nerve Growth Factors
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Issue Date: 16-Nov-2017
Abstract: The aim of the research is to study the human leukocyte antigen (HLA) class II allele frequencies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) associated with anti-neurofascin 155 (NF155) antibodies. Thirteen anti-NF155+ and 35 anti-NF155 negative (anti-NF155neg) CIDP patients were included in a case-control study. The frequencies of the DRB1 HLA allele were analyzed in all patients while DQ frequencies were only studied in patients sharing the DRB1*15 allele. In silico HLA-peptide binding and NF155 antigenicity, predictions were performed to analyze overlap between presented peptides and antigenic regions. DRB1*15 alleles (DRB1*15:01 and DRB1*15:02) were present in 10 out of 13 anti-NF155+ CIDP patients and in only 5 out of 35 anti-NF155neg CIDP patients (77 vs 14%; OR = 20, CI = 4.035 to 99.13). DRB1*15 alleles appeared also in significantly higher proportions in anti-NF155+ CIDP than in normal population (77 vs 17%; OR = 16.9, CI = 4.434 to 57.30). Seven anti-NF155+ CIDP patients (53%) and 5 anti-NF155neg CIDP patients had the DRB1*15:01 allele (OR = 7, p = 0.009), while 3 anti-NF155+ CIDP patients and none of the anti-NF155neg CIDP patients had the DRB1*15:02 allele (OR = 23.6, p = 0.016). In silico analysis of the NF155 peptides binding to DRB1*15 alleles showed significant overlap in the peptides presented by the 15:01 and 15:02 alleles, suggesting functional homology. DRB1*15 alleles are the first strong risk factor associated to a CIDP subset, providing additional evidence that anti-NF155+ CIDP patients constitute a differentiated disease within the CIDP syndrome.
URI: http://hdl.handle.net/10668/11806
metadata.dc.identifier.doi: 10.1186/s12974-017-0996-1
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5691853.pdf517,38 kBAdobe PDFView/Open


This item is protected by original copyright



This item is licensed under a Creative Commons License Creative Commons